Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Osteoporosis
•
Bisphosphonate
Do you use bisphosphonates in combination with SERMs in female patients with progressive decline in bone density despite being on a SERM for post-menopausal symptoms other than osteoporosis?
Related Questions
Is there any contraindication for use of Invisalign teeth aligners in patients undergoing treatment for osteoporosis?
For postmenopausal osteoporosis, would you give denosumab after a course of teriparatide and romosozumab to women who had an atypical femoral fracture while on bisphosphonate therapy a few years earlier?
Do you recommend adjusting the duration of a drug holiday based on the specific bisphosphonate used when treating osteoporosis?
How long after parathyroidectomy (for parathyroid adenoma with hyperparathyroidism) do you wait before initiating romosuzumab in an older patient with osteoporosis and very high fracture risk?
Are there any concerns with live vaccine innoculation and patients who are on denosumab?
What is your experience with using anabolic therapy for treatment of osteoporosis in patients with EtOH cirrhosis and is one agent preferred over another (PTH analogue vs Evenity)?
How do you approach management of osteoporosis in patients post lung transplant?
Would you ever consider retreatment with an antiresorptive medication in a patient with a remote history of atypical fracture attributed to an oral bisphosphonate?
Would you stop romosozumab if a patient developed mild asymptomatic hypocalcemia while on treatment?
Would you have concerns with continuing denosumab for much longer than the available ten year clinical safety trial data for an individual with renal insufficiency with persistent osteoporosis/history of compression fractures?
